According to Zacks, Wall Street analysts forecast sales of $82.29 million in the current quarter for Imperva Inc (NYSE:$IMPV). Among the seven analysts currently covering the company, the lowest estimate was $82.01 million and the highest was $82.98 million. During the same quarter last year, Imperva reported sales of $68.41 million. The firm is scheduled to officially report its earnings on Thursday, November 2nd for the quarter.

Zacks also said that estimates for full-year revenue ranged from $320.90 million to $322.76 million.

On Thursday, shares of Imperva opened at $43.75. The company has a current 52 week low of $34.40 and a 52 week high of $57.24. They have 50 and 200-day moving averages of $44.11 and $45.69. Their market cap is $1.48 billion.

Imperva’s last quarterly earnings results were reported on Thursday, July 27th. They reported an EPS of -$0.10 for the quarter, which was well below the consensus estimates of $0.05. During the same quarter last year, the company had an EPS of -$0.23. During the report, the company also announced total revenue of $74.44 million compared to consensus estimates of $74.30 million. This represented a 28.6% increase in revenue since the same quarter last year.

Multiple analysts have weighed in on the stock recently:

• BidaskClub: In a report on Wednesday, July 5th, this firm dropped their rating from ‘Strong-Buy’ to ‘Buy’.
• Stifel Nicolaus: In a report on Friday, July 14th, this firm issued a rating of ‘Hold’ and set a target price of $47.00.
• Monness Crespi & Hardt: In a report on Friday, July 28th, this firm gave the stock a ‘Buy’ rating and raised their target price from $55.00 to $57.00.

• Evercore ISI (NYSE:$EVR): In a report on Thursday, August 10th, Evercore gave the company a ‘Buy’ rating and set a target price of $56.00.
• Piper Jaffray Companies (NYSE:$PJC): In a report on Monday, August 28th Piper Jaffray gave the stock a rating of ‘Buy’ and issued a target price of $58.00.

In total, the stock has been issued 12 ‘Buy’ ratings, 8 ‘Hold’ ratings, and 1 ‘Sell’ rating.

In insider news, Director Anthony J. Bettencourt sold 99,598 shares of Imperva for an average price of $43.59 per share and a total price of $4,341,476.82. The sale took place on Thursday, August 24th. Bettencourt now owns 99,598 shares of the company worth approximately $4,341,476.82. Insider ownership accounts for 2.20% of the company’s stock.

Multiple institutions recently altered their positions in the company:

• UBS Asset Management Americas Inc. bought an additional 7,189 shares in the first quarter, an increase of 107.3%, for a total of 13,889 shares valued at $570,000.
• Comerica Bank (NYSE:$CMA) bought a new position in the company during the first quarter with an opening purchase of $850,000 worth of shares.
• Bank of New York Mellon Corp (NYSE:$BK) bought an additional 2,295 shares in the 1st quarter, an increase of 1.9% for a total of 125,398 shares valued at $5,148,000.
• US Bancorp DE (NYSE:$UBS) bought an additional 3,163 shares in the first quarter, an increase of 142.3%, for a grand total of 5,386 shares valued at $221,000.
• Wells Fargo & Company MN (NYSE:$WFC) bought an additional 25,530 shares in the 1st quarter, an increase of 33.2% , for a total of 102,511 shares valued at $4,208,000.

Institutional ownership currently accounts for 92.72% of the company’s stock.

Featured Image: twitter